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Abstract
Background: Adequate expansion is critical to achieve optimal Bioresorbable Vascular Scaffolds (BVS) apposition to
the vessel wall. However, compared to metallic stents, BVS present different mechanical properties. Hence, slow
deployment and maintenance of balloon inflation for at least 30” is recommended for BVS implantation. However,
since no evidences are available demonstrating the superiority of a longer balloon dilatation time, the implantation
technique is highly variable among different centers.
Methods: A total of 24 BVS-treated lesions were included in the present analysis. After BVS deployment at 12
atmosphere (ATM) the balloon was rapidly deflated and scaffold expansion was documented with an angiogram.
The same balloon was then inflated again and kept at 12 ATM for 30”. Finally, a further angiogram was obtained to
evaluate BVS expansion. Quantitative coronary angiography (QCA) was performed at each step.
Results: A significant increase of minimal luminal diameter (MLD)-to-reference scaffold diameter (RSD) ratio
(MLD to RSD Ration, MR-Ratio) from 0.70 ± 0.10 after initial stent deployment to 0.79 ± 0.10 after the 30”-long
balloon dilation was observed (p < 0.001). Of note, this result was consistent across all sub-segments, as well as
across almost all lesion subgroups. A substantial reduction in the prevalence of residual stenosis from 29 % to
17 % was registered after the 30”-long dilation.
Conclusions: Our results strongly support the maintenance of balloon inflation for at least 30” during BVS
deployment to achieve optimal scaffold expansion and minimize the occurrence of residual stenosis.
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Background
Bioresorbable vascular scaffolds (BVS) are a promising
new development with the potential to overcome several
limitations of permanent metallic coronary stents [1–4].
In fact, the special chemical properties of the poly-L-lactic
acid (PLLA) polymer allow complete struts resorption
with multiple potential benefits, including restoration of
normal vasoreactivity [4–6], preservation of physiologic
vascular remodeling and reduction of the risk of late stent
thrombosis [2, 3]. In addition, struts resorption preserves
the possibility of a future surgical myocardial revascu-
larization. Finally, the intrinsic properties of the scaffold
allow undisturbed imaging with computer tomography
and magnetic resonance.
It is well known that prolonged balloon inflation is su-
perior to a rapid inflation/deflation during implantation
of metallic stents [7]. Since bioresorbable scaffolds do
not have the same radial strength observed with metallic
stents, an optimal implantation technique may be even
more important to achieve maximal expansion and pre-
vent strut malapposition [8, 9]. Furthermore, given the
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almost doubled strut thickness of BVS compared to me-
tallic scaffolds, it is important to achieve the largest pos-
sible luminal area to warrant the best fluido-dynamic
conditions and prevent the risk for restenosis and stent
thrombosis [10–12]. For these reasons, the producer
suggests the following implantation protocol: slow BVS
release with stepwise balloon inflation going up whit 2
ATM every 5 seconds, until the scaffold is completely
expanded. At this point, the inflation pressure must be
maintained for at least 30”. Finally, post-dilatation is
possible at operator’s discretion whit either the delivery
system, or with a non-compliant balloon (up to 0.5 mm
larger than the implanted scaffold), to pursue optimal
scaffold implantation. Accordingly, gradual scaffold de-
ployment “pressurizing the delivery system in 2 ATM
increments every five seconds” was also recommended
in a recently published perspective document on tech-
nical aspects in PCI with BVS [13]. This recommenda-
tion was only supported by expert consensus, since no
evidence is available, yet. This is an important issue,
since the 30”-long balloon inflation step suggested by
the producer is underused in few laboratories for several
reasons, including the lack of published studies demon-
strating the importance of such approach. If optimal stent
implantation is undoubtedly effective in reducing the risk
of malapposition for metallic platform, the implantation
technique for bioresorbable scaffold is even more import-
ant, given the mechanical properties of BVSs. In light of
the key importance of an optimal implantation technique,
and in consideration of the still limited experience with
such device, aim of the present studies was to evaluate the
influence of a 30"-long balloon inflation on scaffold expan-
sion, in coronary lesions treated with percutaneous angio-
plasty and implantation of an Absorb.
Methods
Bioresorbable vascular scaffold
The commercially available bioresorbable balloon expand-
able device (1.1 BVS revision, Abbott Vascular, Santa
Clara, CA, USA) was used in the present study. It consists
of a polymer backbone of poly-L-lactide (PLLA) coated
with a thin layer of a 1:1 mixture of an amorphous matrix
of poly-D,L-lactide (PDLLA), and 100 micrograms/cm2 of
the anti-proliferative drug everolimus. The scaffold is
radiolucent, but is provided with a platinum marker
at each end that allows its visualization at fluoros-
copy. Both PLLA and PDLLA are fully resorbable.
The time for complete absorption of the polymer
backbone is predicted to be about 2 years from pre-
clinical studies however it can take longer times in
humans [14]. The scaffold consists of 150 μm thick-struts
arranged as in-phase zigzag hoops linked together by
three longitudinal bridges. The device can be stored at
room temperature.
Study design and population
Consecutive coronary artery lesions treated with a sec-
ond generation BVS (Abbott Vascular, Santa Clara, CA,
USA) at the Division of Cardiology of the university
Magna Graecia, Italy, in patients fulfilling the inclusion
criteria, were included in the present analysis. Only lesions
with adequate angiographic result after pre-dilation were
selected for the study. The BVS was implanted through a
stepwise balloon dilation, consisting in 2 ATM increments
every 5 seconds up to 12 ATM. At this point the balloon
was rapidly deflated and stent expansion documented with
an angiogram. Then, the same balloon was quickly inflated
again and kept at 12 ATM for 30 seconds. At this point
the balloon was newly deflated and a further angiogram
was obtained to re-evaluate BVS expansion. Any further
post-dilatation was left at the operator’s discretion. The
primary study endpoint was the comparison of minimal
scaffold diameter to reference stent diameter ratio (MR-
Ratio) before and after the 30“-long balloon dilation.
Based on previous data from the available literature, we
calculated that a sample size of 24 lesions would have
provided a 90 % power whit a 5 % -error. Secondary end-
points were: the difference in luminal diameter in all scaf-
fold sub-segments (proximal edge, proximal minimum
diameter, central minimum diameter, distal minimum
diameter and distal edge) before and after the 30”-long
balloon dilation. The study protocol was approved by the
local Ethics Review Board (Comitato Etico Regionale,
Sezione Area Centro, Regione Calabria). A written con-
sent was obtained by all patients.
Quantitative coronary angiography
Scaffold expansion was measured at all time points using
quantitative coronary angiography (QCA). For this aim,
coronary angiograms were obtained after lesion predila-
tation, and after every step of scaffold deployment. For
all angiograms, 8 ml (right coronary artery) or 12 ml
(left coronary artery) of the contrast agent iomerol
(Iomeron400®, Bracco Imaging) was injected with the
use of a power injector (ACIST CMS2000, Bracco Imaging)
at 3 ml/s (right coronary artery) or 4 ml/s (left coronary ar-
tery) injection rate with a pressure of 460 psi (right coron-
ary artery) or 605 psi (left coronary artery). QCA was
performed offline by two independent operators using
angiograms that had passed the quality check (Additional
file 1: Figure S1). In particular, a rapid and complete filling
of the epicardial segment with the contrast agent was an
important selection criteria for this study. Reference diam-
eter (RD), minimal luminal diameter (MLD), minimal
luminal diameter to reference scaffold diameter ratio (MR-
Ratio), proximal edge diameter, distal edge diameter and
percentage diameter stenosis were calculated offline.
Optimum scaffold deployment according to QCA was de-
fined as a residual diameter stenosis of less than 10 %.
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Statistical analysis
Continuous variables were expressed as a mean ± standard
deviation, while categorical variables were presented as
counts (%). The Wilcoxon test was used for comparison
of continuous variables between paired groups, including
the primary endpoint analysis. A p value of 0.05 was set as
the threshold for statistical significance. All calculations
were made with SPSS 15 software version (SPSS, Chicago
IL) or Prism 5.0c.
Results
Baseline characteristics
A total of 24 consecutive lesions treated whit a BVS
(Absorb) in 22 patients from July 2013 to January 2014
fulfilling the inclusion criteria were selected for the
present study. Baseline patients’ characteristics and basal
cardiovascular risk profile are reported in Table 1. Of all
included patients, 9 (39 %) had stable angina (CAD),
while 13 (61 %) presented an Acute Coronary Syndrome
(ACS). In this last group 4 patients had unstable angina
(UA), 7 had a non-ST-elevation Myocardial Infarction
(NSTEMI) and 2 an ST-elevation Myocardial Infarction
(STEMI). Angiographic population characteristics are
shown in Table 2.
Scaffold expansion
A significant increase of the minimal luminal diameter
(MLD) to reference scaffold diameter (RSD) ratio (MR-
Ratio) from 0.70 ± 0.10 after initial stent deployment to
0.79 ± 0.10 (p < 0.001) after the 30”-long balloon dilation
was observed (Table 3; Fig. 1). Of note, this result was
consistent across all sub-segments, even though this ef-
fect was more pronounced within the central segment
(Table 3; Fig. 2). Most important, these results were as-
sociated with a substantial reduction in the prevalence
of residual stenosis from 29 % after BVS deployment to
17 % after the 30 %-long dilation (p = 0.001) (Fig. 3).
Intracoronary imaging by means of optical coherence
tomography (OCT) was obtained in a small series of three
further patients, showing similar results as those obtained
by means of QCA. In fact, MR-Ratio was increased from
0,83 ± 0,08 after BVS deployment to 0,93 ± 0,12 after
the 30”-long balloon dilation. Interestingly, OCT ana-
lysis revealed a 33 % relative reduction in the number
of malapposed struts after the 30”-long BVS dilation.
Representative results with OCT imaging are reported
in Fig. 4.
In the group with a nominal scaffold diameter (NSD)
of 2.5 mm, the mean MLD increased from 2.03 ± 0.27 to
2.22 ± 0.32 within the proximal segment (p = 0.003),
from 1.97 ± 0.4 to 2.13 ± 0.31 mm within the central seg-
ment (p = 0.003) and from 2.00 ± 0.21 to 2.14 ± 0.20 mm
within the distal segment (p = 0.025). In the group with a
NSD of 3.0 mm, the mean MLD increased from 2.49 ±
0.25 to 2.68 ± 0.34 mm within proximal segment (p =
0.014), from 2.3 ± 0.28 to 2.54 ± 0.36 mm within the
central segment (p = 0.008) and from 2.48 ± 0.31 to
2.61 ± 0.27 mm within the distal segment (p = 0.014).
Finally, in the group with a NSD of 3.5 mm, the
mean MLD increased from 2.71 ± 0.17 to 2.95 ± 0.14 mm
within the proximal segment (p = 0.125), from 2.46 ± 0.46
Table 1 Patient demographics characteristics (22 patients)
Age (mean ± SD; median) 61 ± 8.2; 60.5
Males (%) 17 (77 %)
Stable Angina (%) 9 (39 %)
Acute Coronary Sindrome 13 (61 %)
Unstable Angina (%) 4 (18 %)
NSTEMI (%) 7 (32 %)
STEMI (%) 2 (9 %)
Hypertension (%) 16 (72 %)
Hypercolesterolemia (%) 10 (45 %)
Diabetes Mellitus (%) 6 (27 %)
Smokers (%) 6 (27 %)
Previous AMI (%) 6 (27 %)
Previus-PTCA (%) 5 (23 %)
Cronic Kidney Disease (%) 2 (9 %)
NSTEMI non-ST segment elevation acute myocardial infarction, STEMI ST
segment elevation acute myocardial infarction, PTCA percutaneous transcatheter
coronary angioplasty
Table 2 Procedural characteristics (n = 24)
Target vessel LAD 8
LCX 11
RCA 5




RVD ≥2,5 mm 8
<2,5 mm 16
Balloon Ratio ≥1 9
<1 15
Balloon Pre-dilatation Length ≥12 mm 15
<12 mm 9
Scaffold Diameter 2,5 mm 12
3 mm 8
3,5 mm 4
Scaffold Length ≥20 mm 4
<20 mm 20
LAD left anterior descendant, LCX left circumflex artery, RCA right coronary
artery, SVD single-vessel disease, CAD stable coronary artery disease, ACS acute
coronary syndrome, MVD multiple-vessel disease, RVD reference
vessel diameter
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to 2.70 ± 0.57 mm the central segment (p < 0.125) and
from 2.68 ± 0.42 to 2.82 ± 0.32 mm within the distal seg-
ment (p = 0.125) The lack of statistical significance within
the group with a NSD of 3.5 mm is clearly due to the
number of lesion in this group (Table 4; Additional file 2:
Figure S2).
Furthermore, we also evaluated the effect of the 30”-
long balloon dilation across different lesion subgroups
(Additional file 2: Figure S2). Interestingly, the result of
a better scaffold expansion after the 30”-long balloon
dilatation was consistent across all lesion subgroups,
with only two exception: lesion in which scaffold length
was > 20 mm (n = 4) and lesions where a 3.5-diameter
scaffold was implanted (n = 4). In these case the lack of a
statistically significance may be related to the limited
number of lesions in these subgroups. Finally, at mul-
tivariable analysis renal insufficiency (p = 0.021) and
diabetes (p = 0.037) were the only independent predic-
tors of the acute gain after the 30”-long dilation,
while neither the balloon-to-BVS ratio (p = 0.726), nor
hypercholesterolemia (p = 0.362), nor the presence of an
ACS (p = 0.273) were significant predictors.
Scaffold post-dilation
Although the impact of post-dilation was not a direct
objective of the present study, in 12 cases a post-dilation
by means of a non-compliant balloon (NC balloon) was
performed after scaffold implantation, at operator’s dis-
cretion. The diameter of the NC balloon was equal to
the nominal scaffold diameter in 7 cases, and 0.25 mm
larger than nominal scaffold diameter in 5 cases. Inter-
estingly, the impact of additional post dilation by means
of a non-compliant was very limited. In fact, the further
increase of the MR-ratio was virtually comparable at the
proximal (0,85 ± 0,11 to 0,885 ± 0,09; p = ns), the central
(0,80 ± 0,08 to 0.81 ± 0,09; p = ns) and the distal (0,83 ±
0,07 to 0.85 ± 0,08; p = ns) segments.
Discussion
The main finding of the present study is that duration of
balloon inflation during the release of the device has a
significant impact on the acute gain after BVS implant-
ation. This result is particularly relevant, since the 30”-
long dilation significantly improved scaffold expansion
in all sub-segments and in almost all lesion subgroups.
Our findings have practical relevance, as it is known that
an optimal implantation technique is the key to prevent
adverse events during the follow up.
In fact, among the major concerns with BVSs are scaf-
fold under-expansion and acute elastic recoil of the ves-
sel wall [9, 10, 14]. On the contrary, the present study
revealed a good acute performance of BVS, when a
proper implantation technique is applied to suitable
lesions. This is an important confirmation for BVS effi-
cacy, since both suboptimal deployment and a lower
acute gain are associated to a higher incidence of target
lesion failure and subsequent revascularization [15–18].
Of note the significant increase in the mean minimal
lumen diameter documented in the present study after a
longer balloon dilatation was responsible for a substan-
tial reduction of the prevalence of residual stenosis from
29 % to 17 %. Even though our results only apply to a
selected lesion subset, namely those that could be opti-
mally pre-dilated, a proper implantation technique could
be even more important in a broader lesion subset.
However, specific studies are needed to evaluate the
Table 3 MR-Ratio scaffold measurement (n = 24)
QCA Variables Deployment (MR-Ratio) Long dilation (MR-Ratio) Increase p value
Minimal lumen diameter (mean; SD) 0.70 ± 0.10 0.79 ± 0.10 9 % <0.001
Proximal MLD scaffold diameter (mean; SD) 0.80 ± 0.09 0.87 ± 0.11 7 % <0.001
Central MLD scaffold diameter (mean; SD) 0.76 ± 0.12 0.83 ± 0.11 7 % <0.001
Distal MLD scaffold diameter (mean; SD) 0.79 ± 0.08 0.84 ± 0.08 5 % <0.001
Proximal edge (mean; SD) 0.88 ± 0.18 0.95 ± 0.16 7 % <0.001
Distal edge (mean; SD) 0.80 ± 0.09 0.84 ± 0.11 4 % <0.001
MLD minimal luminal diameter, MR-Ratio =MLD-to-reference scaffold diameter Ratio; SD standard deviation
Fig. 1 MLD-to-nominal scaffold diameter Ratio (MR-Ratio) before
and after the 30”-long balloon dilation. Points represent pre- and
post-dilation values for each lesion. Within the boxplots the mean
(horizontal line) the interquartile range (box ends) and the 95 %
Confidence Interval (whiskers) are reported
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optimal implantation technique in a larger, unselected
lesion set. Notwithstanding the initial enthusiasm around
bioresorbable vascular scaffolds, that drove some centers
to immediately reduce the selection criteria for BVS
implantation, caution should be used, given the still
limited experience with these devices. In particular, the
bulky struts with larger luminal protrusion compared to
metallic stents mandate maximal effort for prevention of
malapposition. Of note, a lower renal function was associ-
ated to a lower increase in minimal scaffold diameter at
Fig. 3 Prevalence of >10 % residual stenosis before (white bar) and
after (black bar) the 30”-long balloon dilation
Fig. 4 Illustrative example of the measurements obtained through
OCT. Minimal Diameter, Mean Diameter and Lumen Area of
Bioresorbable vascular scaffolds (BVS): before (a) and after (b) the
30”-long balloon dilation
Fig. 2 Mean MLD-to-nominal scaffold diameter Ratio (MR-Ratio)
before and after the 30”-long balloon dilation for each scaffolded
sub-segments: proximal (panel a) median (panel b) and distal (panel c)
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multivariable analysis, in the present study. The concerns
about an unrestricted use of BVS are also supported by
the evidence that reabsorption time is actually longer
than initially expected [19]. The present study fills a
lack of evidence. In fact, despite a more gradual and
longer deployment than usually done with metallic stents
is both suggested by the producer and endorsed in a re-
cent expert review [13], no direct experimental evidence
was available, yet.
Conclusions
A correct and careful implantation technique including
a 30”-long balloon dilation is key for a successful im-
plantation, and to achieve maximal scaffold expansion.
Proper stent deployment minimizes the prevalence of post-
PCI residual stenoses. BVSs are a major breakthrough in
the field of coronary interventions.
Limitations
The main limitation of the present study is the lack of
intracoronary imaging. For this reason, we couldn’t evalu-
ate malapposition. However, such evaluation would have
required removal of the balloon catheter after scaffold de-
ployment, introduction of the imaging catheter, and an-
other exchange to the balloon catheter to perform the 30”-
long dilation. Finally, after removal of the catheter a new
run with the imaging catheter would make required the
introduction of a further intracoronary device. In other
words, this would have required a significant prolongation
of both total procedural time and radiation dose. However,
the specific aim of the present study was to evaluate the in-
ternal coronary diameter at the different balloon inflation
steps, therefore the QCA is appropriate technology to this
end. Finally, since optimal lesion pre-dilatation was an in-
clusion criterium for the present study our conclusions
cannot be generalized to a different population. In fact,
despite BVS implantation is not recommended in lesions
with suboptimal response to pre-dilatation, several opera-
tors are implanting BVSs in unselected lesions.
Additional files
Additional file 1: Figure S1. Inter-observer variability of QCA
measurement. QCA = quantitative coronary angiography. (TIFF 2932 kb)
Additional file 2: Figure S2. Delta change of MR-Ratio after the
30”-long balloon dilation in study subgroups. stable ACS = acute coronary
syndrome; CAD = coronary artery disease; Balloon Ratio = pre-dilatation
balloon diameter-to-nominal scaffold diameter Ratio; RVD = reference
vessel diameter. (TIFF 2932 kb)
Abbreviations
ACS: Acute coronary syndrome; ATM: Atmosphere; Balloon Ratio:
pre-dilatation balloon diameter-to-nominal scaffold diameter Ratio;
BVS: Bioresorbable vascular scaffolds; CAD: Coronary artery disease;
MLD: Minimal luminal diameter; MSD: Minimal scaffold diameter;
MR-Ratio: MLD-to-nominal scaffold diameter Ratio; NSD: Nominal scaffold
diameter; NSTEMI: Non-ST-elevation Myocardial Infarction; PLLA: poly-L-lactic
acid; PDLLA: poly-D,L-lactide; PSI: Pound-force per square inch;
QCA: Quantitative coronary angiography; RSD: Reference scaffold diameter;
RVD: Reference vessel diameter; STEMI: ST-elevation Myocardial Infarction;
TLF: Target lesion failure; TVF: Target vessel failure; UA: Unstable angina.
Competing interests
CI received research and educational grants from Abbott vascular
(not for this specific study).
Authors’ contributions
SS conceived of the study, contributed to the preparation and critical review
of the manuscript. SD participated in the design of the study and performed
the statistical analysis, contributed to the preparation and critical review of
the manuscript. GA; AM and CS performed the QCA analysis. AP, JS, DT and
GC contributed to the preparation and critical review of the manuscript. CI
conceived of the study, and participated in its design and coordination and
helped to draft the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
This study was partly supported by a grant of the Italian Ministry of
Education, University and Research (MIUR): PON01_02833 “CARDIO-TECH”.
Author details
1Division of Cardiology, Department of Medical and Surgical Sciences, Magna
Graecia University, Catanzaro, Italy. 2URT-CNR, Magna Graecia University,
Catanzaro, Italy. 3Department of Medical and Surgical Sciences and Director,
URT Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University,
Catanzaro 88100, Italy.
Received: 12 May 2015 Accepted: 4 December 2015
References
1. Ormiston J, Serruys PW, Regar E, Dudek D, Thuesen L, Webster M, et al.
A bioabsorbable everolimus-eluting coronary stent system for patients with
single de-novo coronary artery lesions (ABSORB): a prospective open-label
trial. Lancet. 2008;371:899–907.
2. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM,
et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB):
2-year outcomes and results from multiple imaging methods. Lancet.
2009;373:897–910.
3. Serruys PW, Onuma Y, Ormiston JA, De Bruyne B, Regar E, Dudek D, et al.
Evaluation of the second generation of a bioresorbable everolimus
drug-eluting vascular scaffold for treatment of de novo coronary artery
stenosis: Six-month clinical and imaging outcomes. Circulation.
2010;122:2301–12.
4. Onuma Y, Serruys PW. Bioresorbable scaffold: The advent of a new era in
percutaneous coronary and peripheral revascularization? Circulation.
2011;123:779–97.
5. Sarno G, Bruining N, Onuma Y, Garg S, Brugaletta S, De Winter S, et al.
Morphological and functional evaluation of the bioresorption of the
bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity
Table 4 MLD in all sub-segments (n = 24)
MLD (mean, SD) Sub-segment Deployment Long dilation p value
Proximal 2.03 ± 0.27 2.22 ± 0.32 0.003
2.5 mm (n = 12) Central 1.97 ± 0.4 2.13 ± 0.31 0.003
Distal 2.0 ± 0.21 2.14 ± 0.2 0.025
Proximal 2.49 ± 0.25 2.68 ± 0.34 0.014
3 mm (n = 8) Central 2.3 ± 0.28 2.54 ± 0.36 0.008
Distal 2.48 ± 0.31 2.61 ± 0.27 0.014
Proximal 2.71 ± 0.17 2.95 ± 0.14 0.125
3.5 mm (n = 4) Central 2.46 ± 0.46 2.70 ± 0.57 0.125
Distal 2.68 ± 0.42 2.82 ± 0.32 0.125
MLD minimal luminal diameter, MR-Ratio = MLD-to-reference scaffold diameter
Ratio, SD standard deviation
Sorrentino et al. BMC Cardiovascular Disorders  (2015) 15:169 Page 6 of 7
and vasomotion testing at two year follow-up: A patient level insight into
the ABSORB A clinical trial. Int J Cardiovasc Imaging. 2012;28:51–8.
6. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al.
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
J Am Coll Cardiol. 2005;46:231–6.
7. Cook JR, Mhatre A, Wang FW, Uretsky BF. Prolonged High-Pressure is
Required for Optimal Stent Deployment as Assessed by Optical Coherence
Tomography. Catheter Cardiovasc Interv. 2014;83:521–7.
8. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric
vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv. 2011;4:535–8.
9. Jaguszewski M, Wyss C, Alibegovic J, Luscher TF, Templin C. Acute
thrombosis of bioabsorbable scaffold in a patient with acute coronary
syndrome. Eur Heart J. 2013;34:2046.
10. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al.
Incomplete stent apposition and very late stent thrombosis after
drug-eluting stent implantation. Circulation. 2007;115:2426–34.
11. Steinberg DH, Mintz GS, Mandinov L, Yu A, Ellis SG, Grube E, et al.
Long-term impact of routinely detected early and late incomplete stent
apposition: an integrated intravascular ultrasound analysis of the TAXUS IV,
V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies.
JACC Cardiovasc Interv. 2010;3:486–94.
12. Indolfi C, Piscione F, Ceravolo R, Maione A, Focaccio A, Rao MA, et al.
Limb Vasoconstriction After Successful Angioplasty of the Left Anterior
Descending Coronary Artery. Circulation. 1995;92:2109–12.
13. Tamburino C, Latib A, van Geuns RJ, Sabate M, Mehilli J, Gori T, et al.
Contemporary practice and technical aspects in coronary intervention
with bioresorbable scaffolds: a European perspective. EuroIntervention.
2015; doi:10.4244/EIJY15M01_05.
14. Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, et al.
ABSORB Cohort A and B investigators. Comparison of in vivo acute stent
recoil between the bioresorbable everolimus-eluting coronary scaffolds
(revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
Catheter Cardiovasc Interv. 2011;78:3–12.
15. Kay P, Sabaté M, Costa MA, Kozuma K, Albertal M, van der Giessen WJ, et al.
Positive Geometric Vascular Remodeling Is Seen After Catheter-Based
Radiation Followed by Conventional Stent Implantation but Not After
Radioactive Stent Implantation. Circulation. 2000;102:1434–9.
16. Sianos G, Kay IP, Costa MA, Regar E, Kozuma K, de Feyter PJ, et al.
Geographical miss during catheter-based intracoronary beta-radiation:
incidence and implications in the BRIE study. Beta-Radiation In Europe.
J Am Coll Cardiol. 2001;38:415–20.
17. Tahara S, Bezerra HG, Kyono H, Carrigan T, Mehanna E, Wang W, et al.
Impact of acute gain on clinical outcomes of patients treated with
sirolimus-eluting stent. - A sub-analysis study from the STLLR trial.
Circ J. 2011;75:2113–9.
18. Prati F, Kodama T, Romagnoli E, Gatto L, Di Vito L, Ramazzotti V, et al.
Suboptimal stent deployment is associated with subacute stent thrombosis:
Optical coherence tomography insights from a multicenter matched study.
From the CLI Foundation investigators: the CLI-THRO study. Am Heart J.
2015;169(2):249–56.
19. Indolfi C, Mongiardo A, Spaccarotella C, Caiazzo G, Torella D, De Rosa S.
Neointimal proliferation is associated with clinical restenosis 2 years after
fully bioresorbable scaffold. Circ Cardiovasc Imaging. 2014;7(4):755–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sorrentino et al. BMC Cardiovascular Disorders  (2015) 15:169 Page 7 of 7
